Do N-Acetylcystein, ß-Glucan, and Coenzyme Q10 Mollify Myocardial Ischemia-Reperfusion Injury?
Background. N-acetylcysteine, ?-glucan, and coenzyme Q10 have been shown to have antioxidant and anti-inflammatory effects on reperfusion injury. The aim of our study was to determine and evaluate the effects of these agents on myocardial ischemia-reperfusion injury.
Methods. Forty-four New Zealand white rabbits, all female, weighing 2.4 to 4.1 kg (mean, 3.6 kg) were used in the study. Four study groups of 11 animals were arranged by randomization. The groups were the control group (group C), a group premedicated with coenzyme Q10 (group Q), a group premedicated with ?-glucan (group ?T), and a group premedicated with N-acetylcysteine (group N). After exploration of the heart, a basal myocardial biopsy was taken from the anteroapical left ventricle, and the first blood sampling was done before ischemia. For the ischemia-reperfusion experiments, the major left anterior descending artery was occluded after baseline measurements. After a 45-minute transient ischemic period, the heart was perfused for 120 minutes. After perfusion, the second myocardial biopsy was taken from the anteroapical left ventricle, and the second blood sampling was done. Blood and tissue analysis were performed and evaluated statistically.
Results. Baseline and reperfusion levels of glutathione peroxidase, superoxide dismutase, malonyldialdehyde, and nitric oxide changed significantly. While malonyldialdehyde levels increased in group C, they decreased in the other study groups (P =.001). The increases in glutathione peroxidase and superoxide dismutase levels were significant in all groups except group C (P =.0001 and P <.05, respectively). Levels of nitric oxide were found to be decreased in group C, whereas they increased in the other groups (P =.001).
Conclusion. Antioxidant medication may help in lowering the risk of myocardial ischemia-reperfusion injury. All the medications in our study are shown to have effective roles in preventing ischemia-reperfusion injury to some extent through their antioxidant properties.
Andersen LW, Thiis J, Kharazmi A, Rygg I. 1995. The role of N-acetylcysteine administration on the oxidative response of neutrophils during cardiopulmonary bypass. Perfusion 10:21-6.nAydin A, Orhan H, Sayal A, Ozata M, Sahin G, Isimer A. 2001. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem 34:65-70.nCeconi C, Curello S, Cargnoni A, Ferrari R, Albertini A, Visioli O. 1988. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetylcysteine. J Mol Cell Cardiol 20:5-13.nChello M, Mastroroberto P, Romano R, et al. 1994. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 58:1427-32.nChew GT, Watts GF. 2004. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis.’ Q J Med 97:537-48.nCotgreave IA. 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. In: Antioxidants in Disease Mechanisms and Therapy. Dies H, ed. Academic Press; San Diego, CA: 205-21.nCuzzocrea S, Rossi A, Serraino I, et al. 2004. Role of 5-lipoxygenase in the multiple organ failure induced by zymosan. Int Care Med 30:1935-43.nFitzgerald SP, Campbell JJ, Lamont JV. 1992. The establishment of reference renges for selenium. Selenoenzme glutathione peroxidase and the metalloenzyme superoxide dismutase in blood fractions. The fifth international symposium on selenium in biology and medicine, Tennessee, July 20-23, 1992.nJennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. 1960. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Pathology 70:68-78.nKayali H, Ozdag MF, Kahraman S, et al. 2005. The antioxidant effect of beta-glucan on oxidative stress status in experimental spinal cord injury in rats. Neurosurg Rev 28:298-302.nMarchioli R. 1999. Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol Res 40:227-38.nMenasche P, Grousset C, Gauduel Y, Mouas C, Piwnica A. 1992. Maintenance of the myocardial thiol pool by N-acetylcysteine: an effective means of improving cardioplegic protection. J Thorac Cardiovasc Surg 103:936-44.nMortensen SA. 1996. Coenzyme Q10 treatment may be protective during coronary artery bypass operations. Ann Thorac Surg 62:1243-4.nNaranjan SD, Adel BE, Tomoji H, Naoki M. 2000. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 47:446-56.nOhkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animals and tissues by thiobarbituric acid reaction. Anal Biochem 95:351-8.nOrhan G, Yapici N, Yuksel M, et al. 2006. Effects of N-acetylcysteine on myocardial ischemia reperfusion injury in bypass surgery. Heart Vessels 21:42-7.nPark JL, Lucchesi BR. 1999. Mechanisms of myocardial reperfusion injury. Ann Thorac 68:1905-12.nPleban PA, Munyani A, Bechum J. 1982. Determination of selenium concentration and glutathione peroxidase activity in plasma and erythrocytes. Clin Chem 2:311-6.nRosenfeldt F, Marasco S, Lyon W, et al. 2005. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 129:25-32.nSchaper W, Schaper J. 1997. Reperfusion injury: an opinionated view. J Thrombos Thrombolysis 4:113-6.nSochman J. 2002. N-acetylcysteine in acute cardiology: 10 years later. What do we know and what would we like to know. JACC 9:1422-8.nSunamori M, Tanaka H, Maruyama T, Sultan I, Sakamoto T, Suzuki A. 1991. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc Drugs Ther 5(suppl 2):297-300.nTang LD, Sun JZ, Wu K, Sun CP, Tang ZM. 1991. Beneficial effects of N-acetylcysteine and cysteine in stunned myocardium in perfused rat heart. Br J Pharmacol 102:601-6.nTracey WR, Tse J, Carter G. 1995. Lipopolisaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 272:1011-5.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).